Leukemia and lymphoma are top cancers affecting children, adolescents and young adults with high five-year survival rates. Late effects of these cancers are a concern in reproductive-age patients, ...
12 May 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Leukemia and lymphoma are cancers affecting children, adolescents, and young adults and may affect reproductive outcomes and maternal metabolism. We evaluated for metabolic changes in newborns of m...
Background/Objectives: Antihypertensive treatment is crucial for preventing major adverse cardiovascular events, but suboptimal adherence remains a challenge. Methods: This is a secondary analysis of routine care data from a large pragmatic trial comparing two thiazide diuretics: chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). In the trial, 13,523 older hypertensive patients were randomized from 72 Veterans Affairs medical centers. Medication possession ratio (MPR), reflecting adherence to either study medication (CTD or HCTZ), was used and compared across all randomized patients. Results: The overall median MPR was 95% for all randomized patients and 80% for 6656 individuals who reached 2.4 years for the average follow-up. Lower MPR was observed in Black, separated, urban-living, and comorbid patients. About 30% of the participants (n = 4022) were categorized as non-adherent using a definition of MPR < 80%. Those with baseline systolic blood pressure ≥ 136, recent smoking history, and prior heart failure and Black participants had decreased odds of having an MPR ≥ 80%, while increased odds of reaching that threshold were observed in those who had an eGFR ≥ 60, received ≥3 antihypertensive medications, were married, or resided in rural areas. Conclusions: This analysis provided assessment of real-world medication adherence in a sizable older hypertensive cohort. The proportion of non-adherence found in our analysis was comparable to national trends for US older adults taking blood pressure medications. Identifying sociodemographic characteristics and health conditions associated with non-adherence can help clinicians design targeted interventions for improved adherence to clinically prescribed medications. This is important as hypertension and the older adult population are both expected to grow significantly in the future.
30 January 2026 in Journal of the American Heart Association
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.
Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related characteristics. Such biased selection may make the therapeutic agent seem more or less effective within a certain stratum. While block randomization and an intent-to-treat design can help to minimize confounding within the trial sample, differences may still exist with respect to the distribution of these variables in the population. To mitigate misleading conclusions, the current manuscript illustrates how to ‘population-adjust’ survival estimates in a clinical trial using the Beckett–Bayes expansion method. In contrast to other population adjustment methods, this novel approach involves substituting the probability of belonging to a specific sample stratum with the corresponding population data (i.e., population borrowing). As a regression-free technique, the method is not susceptible to model misspecification. A large clinical trial focusing on cardiovascular-related deaths in patients with hypertension is used as an example to illustrate the method. The proposed framework is promising and easy to implement when reliable population-level information is available.